Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lung cancer, non-small cell
Results 1-25 of 492 for your search:
Start Over
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Status: Active
Phase: Phase IV
Type: Treatment
Age: 70 and over
Trial IDs: 1200.209, NCI-2016-00277, NCT02514174
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: CLI-PHO1601, NCI-2017-00430, NCT02916745
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, S1400I, NCT02154490
Counseling Sessions in Reducing Tobacco Dependence in Participants Undergoing Lung Cancer Screening
Status: Active
Phase: Phase III, Phase II
Type: Behavioral study
Age: 55 to 80
Trial IDs: 2011-541, NCI-2016-01236, NCT02267096
Afatinib Dimaleate with or without Cetuximab in Treating Patients with Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1403, NCI-2014-02405, BI 1200.124, NCT02438722
A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
Status: Not yet active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: BO29554, NCI-2017-01360, 2017-000076-28, NCT03178552
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: LF-0208, NCI-2009-01425, NCT00706862
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
Status: Active
Phase: Phase III
Type: Diagnostic
Age: 18 and over
Trial IDs: AMI-2008-01, NCI-2014-02587, NCT00882609
Standard or Accelerated Hypofractionated Image-Guided Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer and Poor Performance Status
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: STU 052011-093, NCI-2013-00783, NCT01459497
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TV1011-LC-303, NCI-2015-00116, 2012-002447-14, NCT01630733
Patient Navigation Intervention in Improving Surgery Rates in African Americans with Early Stage Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Educational/Counseling/Training, Supportive care
Age: 21 and over
Trial IDs: 01414, NCI-2014-02559, 101487, WF-01414, NCT01885455
Comparing Photon Therapy To Proton Therapy To Treat Patients with Lung Cancer
Status: Active
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: RTOG-1308, NCI-2013-01850, NCT01993810
Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A081105, NCI-2014-01508, CALGB A081105, NCT02193282
Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E4512, NCI-2014-01507, NCT02201992
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BR31, NCI-2015-01967, ACTRN12615000323527, IFCT1401, NCT02273375
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29431, NCI-2015-01580, 2014-003083-21, NCT02409342
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 15540, NCI-2016-00365, 2014-004824-22, I4T-MC-JVCY, NCT02411448
Perioperative Risk Stratification and Risk-Based, Protocol-Driven Management in Reducing Death or Serious Complications in Patients with Cancer Undergoing Surgery
Status: Active
Phase: Phase III
Type: Health services research, Supportive care
Age: 18 and over
Trial IDs: 14-036, NCI-2014-02262, NCT02456389
Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: STU 022015-069, NCI-2015-01676, NCT02468024
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GO29527, NCI-2015-01731, 2014-003205-15, NCT02486718
Nivolumab after Surgery and Chemotherapy in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA5142, NCI-2015-01916, NCT02595944
Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BPI-2358-103, NCI-2015-01970, NCT02504489
Start Over